July 3, 2020 / 12:31 PM / a month ago

BRIEF-Gilead Says European Commission Grants Conditional Marketing Authorization For Veklury (Remdesivir)

July 3 (Reuters) - Gilead Sciences Inc:

* EUROPEAN COMMISSION GRANTS CONDITIONAL MARKETING AUTHORIZATION FOR GILEAD’S VEKLURY® (REMDESIVIR) FOR THE TREATMENT OF COVID-19

* GILEAD SCIENCES - UNDER AUTHORIZATION, VEKLURY IS INDICATED FOR TREATMENT OF COVID-19 IN ADULTS AND ADOLESCENTS WITH PNEUMONIA REQUIRING SUPPLEMENTAL OXYGEN

* GILEAD SCIENCES INC - CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR VEKLURY (REMDESIVIR) IS INITIALLY VALID FOR ONE YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below